Relay Therapeutics, Inc. Common Stock

RLAYNASDAQ • USD
17.27 USD
↘ 0.82 (4.53%)AT CLOSE (03:59 PM EST)
17.44
↗ 0.16 (0.96%)
POST MARKET (AS OF 07:30 PM EST)
Post Market
AS OF 07:30 PM EST
17.44
↗ 0.16 (0.96%)
🔴Market: CLOSED

Relay Therapeutics, Inc. Common Stock (RLAY) trades at $17.27 per share. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, RLAY is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Nov 16, 2026.

Open?$17.81
High?$18.07
Low?$17.22
Prev. Close?$18.09
Volume?1.7M
Avg. Volume?2.6M
VWAP?$17.47
Rel. Volume?0.64x
Bid / Ask
Bid?$17.50 × 700
Ask?$18.10 × 300
Spread?$0.60
Midpoint?$17.80
Valuation & Ratios
Market Cap?3.8B
Shares Out?221.0M
Float?157.6M
Float %?71.9%
P/E Ratio?N/A
P/B Ratio?4.66
EPS?-$1.33
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Employees
218
Market Cap
4.0B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-07-16
Address
60 HAMPSHIRE STREET
CAMBRIDGE, MA 02139
Phone: 617-370-8837
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
17
Short Sent.?
30
Piotroski F-Score?0/9Weak
Altman Z-Score?25.41Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?27.68%Squeeze Risk
Short Interest?43.6M
Days to Cover?20.7
Free Float157.6M
Avg Daily Volume2.1M
Settlement Date2026-10-30
Financial Health
Current Ratio?14.62Strong
Quick Ratio?14.62Strong
Cash Ratio?2.10Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
39
4.66FAIR▾
P/S?
Peers
100
S&P
3
368.69HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-11.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
356.69HIGH▾
Returns & Efficiency
ROE?
S&P
5
-35.9%WEAK▾
ROA?
S&P
3
-32.6%WEAK▾
Cash Flow & Enterprise
FCF?$-214021000
Enterprise Value?$3.7B
Fundamentals ratios updated end of day